IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study
27 févr. 2025 08h05 HE
|
Imunon, Inc.
IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer Patient enrollment in Phase 3 pivotal trial of IMNN-001 scheduled to begin in Q1...
IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19
26 févr. 2025 08h05 HE
|
Imunon, Inc.
Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® technology IMNN-101 induced 2- to 4-fold increase in neutralizing...
IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025
20 févr. 2025 08h30 HE
|
Imunon, Inc.
LAWRENCEVILLE, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company...
IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer
19 févr. 2025 08h05 HE
|
Imunon, Inc.
Data reinforce dose-dependent mechanism with IMNN-001 100mg/m2 dose associated with 20% increase in IL-12 levels compared to 79mg/m2 dose Results from OVATION 2 Study continue to validate TheraPlas®...
IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer
10 févr. 2025 08h05 HE
|
Imunon, Inc.
Dr. Faller joins IMUNON with more than 30 years of industry, academic and laboratory experience, with specialized expertise in oncology and immunology LAWRENCEVILLE, N.J., Feb. 10, 2025 (GLOBE...
IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer
19 déc. 2024 08h05 HE
|
Imunon, Inc.
Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001 Vertical integration of major components assures a high-quality, commercially viable...
IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001
10 déc. 2024 08h05 HE
|
Imunon, Inc.
Based on more than six months of additional monitoring, data show continued improvement in overall survival (OS) in intent-to-treat (ITT) population of women newly diagnosed with advanced ovarian...
IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer
25 nov. 2024 08h05 HE
|
Imunon, Inc.
FDA Project Team supports the company’s proposed Phase 3 trial strategy, including overall trial design, target patient population, treatment schedule, and primary endpoint Final Protocol submission...
IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting
07 nov. 2024 10h00 HE
|
Imunon, Inc.
IMNN-001 immunotherapy plus standard-of-care chemotherapy resulted in 35% improvement in overall survival and 25% improvement in progression-free survival versus standard-of-care alone Treatment was...
IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates
07 nov. 2024 08h05 HE
|
Imunon, Inc.
Conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated...